Navigation Links
ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
Date:3/2/2011

SHANGHAI, March 2, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the fourth quarter and full year 2010 ended December 31, 2010 on March 15, 2011. Management will host a conference call to discuss the results at 8:00am New York Time on March 15, 2011 (8:00pm Beijing time on March 15, 2011).

Conference Call

Mr. Michael Hui, founder and Chief Executive Officer, Mr. Kevin Chen, President and Chief Operating Officer, and William Dai, Chief Financial Officer, will discuss the results and take questions following the prepared remarks.

The dial-in details for the live conference call are as follows:- U.S. Toll Free Number:

1.800.299.9630- International dial-in number:

+ 1.617.786.2904- China Toll Free Number:

10 800 152 1490 (North)10 800 852 1490(South)- Hong Kong Toll Free Number:800 963 844Passcode:

SHPA live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from March 15, 2011 to March 22, 2011. The dial-in details for the replay are as follows:

- U.S. Toll Free Number:

1-888-286-8010- International dial-in number:+1-617-801-6888Passcode:

85666096About ShangPharma Corp.ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, contact:ShangPharma CorporationLan Xie, VP of Finance and OperationsE-mail: IR@shangpharma.comChristensenIn New YorkKimberly Minarovich,Phone: +1 917-533-3268E-mail: kminarovich@christensenir.comIn Hong KongTip FlemingPhone: +852-9212-0684Email: tfleming@ChristensenIR.com  
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dynamic Ventures Corp. Reaches An Agreement in Principle with NOVA Home Loans
2. Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain
3. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
4. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
5. Norgen Biotek Corp. Launches a Novel kit to Collect, Concentrate, Preserve and Isolate DNA, RNA, microRNA and proteins from Urine Specimens
6. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
7. IGEN Networks Corp. obtains Blue Sky Statutory Compliance in 38 States with Approval of Standard & Poors
8. NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
9. FutureFuel Corp. Declares Dividend
10. CRH Medical Corp. Joins OTCQX
11. IGEN Networks Corp. announces new Board member and the cancellation of three million shares for return to treasury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. ... Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate ... U.K. Biobank resource. The initiative will enable researchers to gain ... medicines for a wide range of serious and life threatening ... ...
(Date:3/22/2017)... ... 22, 2017 , ... Researchers face a fundamental challenge as ... full-size tissues, bones, even whole organs to implant in people to treat disease ... into the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
Breaking Biology Technology:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/22/2017)... , March 21, 2017 ... Cloud used by retailers such as 1-800-Flowers and ... platform — Product Recommendations and Replenishment. Using Optimove,s machine ... more personalized product and replenishment recommendations to their ... also on predictions of customer intent drawn from ...
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
Breaking Biology News(10 mins):